HEALTH RESOURCE UTILIZATION (HRU) AND COSTS FOR METASTATIC RENAL CELL CARCINOMA (MRCC) PATIENTS TREATED WITH FIRST-LINE (1L) SYSTEMIC THERAPY IN THE UNITED STATES

被引：0
|
作者：
Mhatre, S. [1 ]
Lin, S. [1 ]
Surinach, A. [2 ]
Vohra, R. [1 ]
Satram-Hoang, S. [1 ]
Simpson, J. [1 ]
Wallen, H. [1 ]
Ogale, S. [1 ]
Gong, J. [3 ]
Pal, S. K. [3 ]
George, D. J. [4 ]
机构：
[1] Genentech Inc, San Francisco, CA 94080 USA
[2] Genesis Res LLC, Hoboken, NJ USA
[3] City Hope Comprehens Canc Ctr, Duarte, CA USA
[4] Duke Univ Hosp, Durham, NC USA
来源：
VALUE IN HEALTH | 2016年 / 19卷 / 07期
关键词：
D O I：
10.1016/j.jval.2016.09.2332
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN256
引用
收藏
页码：A755 / A755
页数：1
相关论文
共 50 条
  • [31] Tolerability of first-line therapy for metastatic renal cell carcinoma
    Porta, Camillo
    Szczylik, Cezary
    CANCER TREATMENT REVIEWS, 2009, 35 (03) : 297 - 307
  • [32] Impact of number of treatment lines following first-line (1L) immuno-oncology (IO) combination on overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC).
    Lemelin, Audreylie
    Ernst, Matthew Scott
    Wells, Connor
    Navani, Vishal
    McGregor, Bradley Alexander
    Wong, Shirley S.
    Pal, Sumanta Monty
    Basappa, Naveen S.
    Kapoor, Anil
    Lee, Jae-Lyun
    Donskov, Frede
    Li, Haoran
    Yuasa, Takeshi
    Chang, Rose
    Huynh, Lynn
    Nguyen, Catherine
    Holub, Ashley
    Clear, Louise
    Duh, Mei Sheng
    Heng, Daniel Yick Chin
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [33] Real world outcomes in metastatic renal cell carcinoma patients treated with sunitinib or pazopanib as first line therapy in the United States
    Smith, Tim
    Maclean, Elizabeth
    Mardekian, Jack
    Abernethy, Amy
    Harnett, James
    Clair, Andrew
    BJU INTERNATIONAL, 2016, 118 : 26 - 27
  • [34] Efficacy of first-line combination therapy in metastatic renal cell carcinoma (mRCC) patients (pts) with poor performance status (PS).
    Carril, Lucia
    Colomba, Emeline
    Romero-Ferreiro, Carmen
    Cerbone, Luigi
    Ratta, Raffaele
    Barthelemy, Philippe
    Vindry, Clarisse
    Cherifi, Francois
    Boughalem, Elouen
    Linassier, Claude
    Fornarini, Giuseppe
    Gross-Goupil, Marine
    Saldana, Carolina
    Soberon, Maria Cruz Martin
    de Velasco, Guillermo
    Pernaut, Cristina
    Silva, Carolina Alves Costa
    Flippot, Ronan
    Escudier, Bernard
    Albiges, Laurence
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [35] Updated outcomes of patients with metastatic non-clear cell renal cell carcinoma (mnccRCC) treated with first-line (1L) therapies: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).
    Takemura, Kosuke
    Graham, Jeffrey
    Maj, David
    Zarba, Martin
    Wells, Connor
    Chehade, Razane El Hajj
    Eid, Marc
    Saad, Eddy
    Saliby, Renee Maria
    Lee, Jae Lyun
    Donskov, Frede
    Beuselinck, Benoit
    Jude, Evon
    McKay, Rana R.
    Basappa, Naveen S.
    Pal, Sumanta Kumar
    Porta, Camillo
    Agarwal, Neeraj
    Choueiri, Toni K.
    Heng, Daniel Yick Chin
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (5_SUPPL)
  • [36] Real-World Outcomes in Patients With Metastatic Renal Cell Carcinoma Treated With First-Line Nivolumab Plus Ipilimumab in the United States
    Doshi, Gurjyot K.
    Osterland, Andrew J.
    Shi, Ping
    Yim, Annette
    Del Tejo, Viviana
    Guttenplan, Sarah B.
    Eiffert, Samantha
    Yin, Xin
    Rosenblatt, Lisa
    Conkling, Paul R.
    JCO CLINICAL CANCER INFORMATICS, 2024, 8
  • [37] yyEfficacy of immune-checkpoint inhibitor (ICI) combination as a first-line (1L) therapy in metastatic renal cell carcinoma (mRCC) with sarcomatoid histology: A systematic review and meta-analysis.
    Siddiqi, Rabbia
    Kumar, Gaurav
    Ijaz, Hafsah
    Naqvi, Syed Arsalan Ahmed
    Ayaz, Ahsan
    Bin Riaz, Zaryab
    Bryce, Alan Haruo
    Ho, Thai Huu
    Bin Riaz, Irbaz
    Singh, Parminder
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [38] HEALTHCARE RESOURCE UTILIZATION (HCRU) AND COST STUDIES IN PATIENTS RECEIVING FIRST-LINE (1L) THERAPY FOR ADVANCED OR METASTATIC UROTHELIAL CARCINOMA (MUC): A SYSTEMATIC LITERATURE REVIEW (SLR)
    Auti, P.
    Braun, N.
    Arca, E.
    Teitsson, S.
    Broughton, E.
    May, J. R.
    Kurt, M.
    Alleman, C.
    VALUE IN HEALTH, 2022, 25 (01) : S70 - S70
  • [39] Economic evaluation of sunitinib versus other new targeted therapies as first-line treatment of metastatic renal cell carcinoma (mRCC) in the United States
    Benedict, A.
    Figlin, R. A.
    Charbonneau, C.
    Kreif, N.
    Hariharan, S.
    Negrier, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [40] Characterizing prior nephrectomy patients with metastatic renal cell carcinoma (mRCC) treated with first-line sunitinib versus interferon-alfa
    Figlin, R. A.
    Hutson, T. E.
    Tomczak, P.
    Michaelson, M. D.
    Bjarnason, G. A.
    Lin, X.
    Lowenthal, S. Pitman
    Korytowsky, B.
    Matczak, E.
    Oudard, S.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S644 - S645
12345